Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2019 | CheckMate 227 dual IO therapy: nivo plus ipilimumab upfront for NSCLC

Solange Peters, MD, PhD, of University Hospital Vaudois, Lausanne, Switzerland, presents the CheckMate 227 trial final analysis (NCT02477826) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Importantly, Prof. Peters highlights that nivolumab and low-dose ipilimumabwere well tolerated in non-small cell lung cancer. After the presentation, Marina Garassino, MD, National Cancer Institute of Milan, Milan, Italy, discusses the results and puts them in context.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.